Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients

Inclusion Criteria: * Scheduled to receive a kidney transplant from a deceased expanded criterion donor (ECD) or a donor cardiac death (DCD) donor that was exposed to no more than 36 hr of cold ischemia prior to transplantation, or scheduled to receive a kidney transplant from a standard criterion donor (SCD) that was exposed to 24-36 hr of cold ischemia prior to transplantation * Willing to use adequate contraception for at least 4 weeks after dosing * Willing and able to provide written Informed Consent and to comply with the requirements of the study Exclusion Criteria: * If female, subject is pregnant or lactating * Known bleeding diathesis * INR at Screening \> 1.5 * Platelet count at Screening below LLN and judged clinically significant * Use of Plavix, anticoagulants other than aspirin, antithrombotics, and/or blood-thinning agents within 10 days prior to study entry * Previous receipt of an organ transplant * Will receive concurrent transplant of any additional organ(s) * Clinically significant active infection at study entry * Surgery within 2 weeks prior to study entry * Believed to have used an illicit drug and/or abused alcohol within 3 months prior to study entry * Presence of a psychiatric illness that might interfere with study participation * Cancer, other than basal cell or squamous cell cancer of the skin, within 2 years prior to study entry * Scheduled to receive a kidney transplant from a low risk donor * Currently participation, or participated within 30 days prior to study entry, in an investigational drug study * Known allergy to kanamycin * History or presence of any medical condition or disease that could place the subject an unacceptable risk for study participation